AnaptysBio, Inc.
Antibodies directed against interleukin 36 receptor (IL-36R)

Last updated:

Abstract:

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Status:
Grant
Type:

Utility

Filling date:

15 Apr 2016

Issue date:

7 Jan 2020